Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo

Nov 01 2017

• By Ian Schofield

Tooth wheel mechanism with DIFFERENT, SIMILAR letters — Sandoz is having another crack at getting its biosimilar pegfilgrastim approved

Related Content

Cinfa Banks On ‘Multi-Layered’ Scientific Advice As It Files For EU Pegfilgrastim Biosimilar Review

Oct 09 2017

Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

Oct 10 2017

More Questions As Biocon Pulls EU Filings For Two Biosimilars

Aug 16 2017

Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback

Jan 27 2017

First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn

Dec 20 2016

Related Companies

Novartis AG

Amgen, Inc.

Coherus Oncology, Inc.

Gedeon Richter Plc.

Viatris Inc.

Biocon, Ltd.

Apotex Inc.

Intas Pharmaceuticals Ltd.

Additional Topics

Europe Biosimilars Drug Review Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window